Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03050853 · ClinicalTrials.gov registry record · NA
The Appeal and Impact of E-cigarettes in Smokers With SMI
A NA study of Schizophrenia and Bipolar Disorder, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 2
- Study locations
NCT03050853 is a NA study of Schizophrenia and Bipolar Disorder that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 240 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (10% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT03050853, a NA study of Schizophrenia and Bipolar Disorder, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate behavioral and psychological appeal, toxicity, and effect of e-cigarettes on smoking behavior and nicotine addiction in chronic smokers with serious mental illness (SMI) who have failed to quit smoking. A total of 240 participants will be enrolled and randomly assigned to either receive a supply of e-cigarettes for 8 weeks plus assessments (baseline \& weeks 2, 4, 6, 8, 13, \& 26) or assessments only. This single-blinded study will provide e-cigarettes and instructions on their safe use. Level of appeal will be inferred from carefully assessed use of e-cigarettes and reduction in combustible tobacco. Qualitative data will also be collected from participants assigned to e-cigarettes, given that unanticipated issues will almost certainly arise in connection with e-cigarette use that can only be captured within a qualitative debriefing at the conclusion of participants' time in the study.
Conditions Studied
Interventions
- BEHAVIORAL E-cigarette
Study Locations (2)
Kentucky
- Centerstone Kentucky - Louisville
Massachusetts
- Vinfen Corp - Lawrence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2021-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03050853
The ClinicalTrials.gov registry entry for NCT03050853 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (10% higher). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which E-cigarette is the first listed.
NCT03050853 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kentucky, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03050853 about?
NCT03050853 is a clinical study titled "The Appeal and Impact of E-cigarettes in Smokers With SMI". This study will evaluate behavioral and psychological appeal, toxicity, and effect of e-cigarettes on smoking behavior and nicotine addiction in chronic smokers with serious mental illness (SMI) who have failed to quit smoking. A total of 240 participants will be enrolled and randomly assigned to ei...
What is the current status of trial NCT03050853?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2017-03-01. Estimated completion is 2021-01-31.
What conditions does trial NCT03050853 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Tobacco Dependence.
What interventions are being tested in trial NCT03050853?
The interventions under investigation include: E-cigarette (BEHAVIORAL).
Who is sponsoring clinical trial NCT03050853?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03050853 being conducted?
This trial has 2 study locations across Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.